The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Thirty-five years on from the FDA's approval of a first monoclonal antibody (mAb), these biologics account for nearly a fifth of the agency's new drug approvals each year. mAbs offer exquisite specificity and affinity for both secreted and cell-surface targets…